877130-28-4

Basic information

• Product Name: (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
• Synonyms: (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;(6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-A)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one;2H-Pyran-2-one, 6-cyclopentyl-6-(2-(2,6-diethyl-4-pyridinyl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-A)pyrimidin-2-yl)methyl)-5,6-dihydro-4-hydroxy-, (6R)-;Filibuvir;Pf-00868554;Unii-198J479Y2l;(2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one
• CAS NO: 877130-28-4
• Molecular Formula: C29H37N5O3
• Molecular Weight: 503.64
• Mol File: 877130-28-4.mol
• Article Data: 6

Chemical Properties

• Appearance: white to beige/
• Density: 1.29
• Storage Temp.: room temp
• Solubility: DMSO: soluble10mg/mL, clear
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one(877130-28-4)
• EPA Substance Registry System: (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one(877130-28-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 877130-28-4(Hazardous Substances Data)

Usage

General Description

(R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one is a chemical compound with a complex molecular structure. It contains a pyranone ring and a pyrimidine ring, as well as various alkyl and alkylaryl groups. The compound also features a hydroxy group and a cyclopentyl ring. The intricate arrangement and combination of these chemical moieties suggest potential pharmacological activity, potentially making it a candidate for further research and development in the pharmaceutical industry.

Upstream product

• 1508308-97-1 C₂₉H₃₆⁽²⁾HN₅O₃ 
• 55293-96-4 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde 
• 927889-49-4 (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-dihydro-2H-pyran-2,4(3H)-dione 
• 927889-50-7 dibenzoyl-L-tartaric acid salt of (R)-6-cyclopentyl-6-(2,6-diethylpyridin-4-yl)ethyl-4-hydroxy-5,6-dihydropyran-2-one 
• 877130-24-0 6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-dihydro-3H-pyran-2,4-dione 
• 1510832-89-9 C₂₄H₃₅NO₆ 
• 1510832-88-8 C₂₁H₃₃NO₃ 
• 1508318-99-7 C₃₁H₄₀N₂O₅ 
• 1510832-90-2 C₃₁H₄₃N₅O₄ 
• 1510832-87-7 C₃₉H₄₈N₆O₅ 
• 1228897-39-9 C₂₁H₂₉NO₃ 
• 1228897-34-4 C₂₁H₂₉NO₃ 

Relevant articles and documents

Synthesis of filibuvir. Part III. Development of a process for the reductive coupling of an aldehyde and a β-keto-lactone

Development of a reductive coupling of a β-keto-lactone and an aldehyde is described, in which the Hantzsch ester serves as an inexpensive and convenient reducing agent. Structural features in the β-keto-lactone rendered standard reductive coupling conditions ineffective, requiring development of a specific addition and temperature protocol. Identification of one of the reactants as Ames positive required a single-digit parts per million control strategy for this impurity in the final active pharmaceutical ingredient (API).

Synthetic route optimization of PF-00868554, an HCV polymerase inhibitor in clinical evaluation

This paper describes the optimization efforts to establish an enabling synthesis to provide multigram quantity of PF-00868554, an HCV polymerase inhibitor currently in phase II clinical evaluations.

METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS

The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).